{"name":"Eagle Pharmaceuticals","slug":"eagle-pharmaceuticals","ticker":"EGRX","exchange":"NASDAQ","domain":"eagleus.com","description":"Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development","hq":"Woodcliff Lake, NJ","founded":0,"employees":"134","ceo":"","sector":"Oncology / Injectable Specialty Pharma","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0.25,"stockChange":0,"stockChangePercent":0,"marketCap":"$3M","metrics":{"revenue":257551008,"revenueGrowth":-12.8,"grossMargin":69.8,"rdSpend":0,"netIncome":11948000,"cash":15354000,"dividendYield":0,"peRatio":2.5,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Fulvestrant for Injectable Suspension","genericName":"Fulvestrant for Injectable Suspension","slug":"fulvestrant-for-injectable-suspension","indication":"Other","status":"phase_1"},{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","indication":"Malignant hyperthermia crisis (acute treatment)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAL02","genericName":"CAL02","slug":"cal02","indication":"Treatment of rheumatoid arthritis","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","indication":"Malignant hyperthermia","status":"phase_2"}]}],"pipeline":[{"name":"Fulvestrant for Injectable Suspension","genericName":"Fulvestrant for Injectable Suspension","slug":"fulvestrant-for-injectable-suspension","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Ryanodex and Standard of Care","genericName":"Ryanodex and Standard of Care","slug":"ryanodex-and-standard-of-care","phase":"phase_3","mechanism":"Ryanodex is a dantrolene sodium formulation that blocks calcium release from the sarcoplasmic reticulum in skeletal muscle by inhibiting the ryanodine receptor.","indications":["Malignant hyperthermia crisis (acute treatment)","Malignant hyperthermia susceptibility (prophylaxis)"],"catalyst":""},{"name":"CAL02","genericName":"CAL02","slug":"cal02","phase":"phase_2","mechanism":"CAL02 is a small molecule that targets the CDK9 enzyme, inhibiting its activity and thereby reducing the expression of inflammatory cytokines.","indications":["Treatment of rheumatoid arthritis"],"catalyst":""},{"name":"Dantrolene sodium for injectable suspension","genericName":"Dantrolene sodium for injectable suspension","slug":"dantrolene-sodium-for-injectable-suspension","phase":"phase_2","mechanism":"Dantrolene sodium works by inhibiting calcium ion release from the sarcoplasmic reticulum, thereby reducing muscle spasticity.","indications":["Malignant hyperthermia","Spinal cord injury","Stroke","Spinal cord injury associated with autonomic dysreflexia","Cerebral palsy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":1,"phase_3":1,"phase_2":2},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"yahoo_finance","revenue":316610000,"revenuePeriod":"2022-12-31","revenueHistory":[{"period":"2022-12-31","value":316610000},{"period":"2021-12-31","value":171546000}],"grossProfit":221674000,"grossProfitHistory":[{"period":"2022-12-31","value":221674000},{"period":"2021-12-31","value":129366000}],"rdSpend":34088000,"rdSpendHistory":[{"period":"2022-12-31","value":34088000},{"period":"2021-12-31","value":51275000}],"sgaSpend":106626000,"operatingIncome":80960000,"operatingIncomeHistory":[{"period":"2022-12-31","value":80960000},{"period":"2021-12-31","value":2769000}],"netIncome":35642000,"netIncomeHistory":[{"period":"2022-12-31","value":35642000},{"period":"2021-12-31","value":-8627000}],"eps":2.73,"epsHistory":[{"period":"2022-12-31","value":2.73},{"period":"2021-12-31","value":-0.66}],"cash":55321000,"cashHistory":[{"period":"2022-12-31","value":55321000},{"period":"2021-12-31","value":97659000}],"totalAssets":406160000,"totalLiabilities":172600000,"totalDebt":64000000,"equity":233560000,"operatingCashflow":50701000,"operatingCashflowHistory":[{"period":"2022-12-31","value":50701000},{"period":"2021-12-31","value":28219000}],"capex":-178000,"capexHistory":[{"period":"2022-12-31","value":-178000},{"period":"2021-12-31","value":-323000}],"freeCashflow":50523000,"dividendsPaid":null,"buybacks":-18004000,"employees":134,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.25,"previousClose":0.25,"fiftyTwoWeekHigh":3.87,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"0.001 - 3.87","fiftyDayAverage":0.3,"twoHundredDayAverage":1.2,"beta":0.6,"enterpriseValue":61970116,"forwardPE":0.1,"priceToBook":0.01,"priceToSales":0.01,"enterpriseToRevenue":0.24,"enterpriseToEbitda":0.99,"pegRatio":0,"ebitda":62327000,"ebitdaMargin":24.2,"freeCashflow":38314752,"operatingCashflow":-9318000,"totalDebt":72454000,"debtToEquity":28.7,"currentRatio":2.16,"returnOnAssets":6.6,"returnOnEquity":4.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0,"institutionHeldPercent":55.2,"sharesOutstanding":13157553,"floatShares":5908682,"sharesShort":350531,"shortRatio":3.91,"shortPercentOfFloat":2.7,"epsTrailing":0.1,"epsForward":3.48,"revenuePerShare":19.68,"bookValue":19.25,"officers":[{"age":62,"name":"Mr. Michael  Graves","title":"CEO & Chairman"},{"age":51,"name":"Mr. Christopher  Krawtschuk CPA","title":"CFO and Principal Financial & Accounting Officer"},{"age":45,"name":"Mr. Daniel  O'Connor","title":"Executive VP, Chief Strategy Officer & Head of Corporate Development"},{"age":null,"name":"Dr. Valentin R. Curt M.D.","title":"Senior Vice President of Clinical Drug Development"},{"age":57,"name":"Ms. Debra Marie Hussain","title":"Senior VP & Head of Commercial"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.eagleus.com","phone":"201 326 5300"}}